New standards for the management of nose vestibule malignancies.

Nasal vestibule carcinoma TNM classification brachytherapy interventional radiotherapy squamous cell carcinoma total rhinectomy

Journal

Acta oto-laryngologica
ISSN: 1651-2251
Titre abrégé: Acta Otolaryngol
Pays: England
ID NLM: 0370354

Informations de publication

Date de publication:
Mar 2023
Historique:
medline: 28 3 2023
pubmed: 2 3 2023
entrez: 1 3 2023
Statut: ppublish

Résumé

Nasal vestibule squamous cell carcinoma (NVSCC) is an ill-defined underestimated condition. To define the current standard of care. We review recent acquisitions concerning clinical features and therapeutic approaches. The current AJCC staging system, which attributes to nasal vestibule the same topographic code as nasal cavity proper and the same T-classification criteria as ethmoid, appears inadequate.As for treatment of primary lesions without bone invasion, current evidence suggests that brachytherapy is at least equivalent to surgery and superior to external beams in terms of oncological outcomes, and superior to both modalities in terms of cosmesis and function. As for classification and staging, the nasal vestibule should be defined as a subsite of the nose and paranasal sinuses, distinct from the 'nasal cavity proper and ethmoid', with specific topographic code and T-classification criteria. This will improve the assessment of prognosis and prevalence, underestimated also because of misdiagnosis with skin cancers.Secondly, brachytherapy should become the new standard for the treatment of primary lesions without bone invasion. To optimize the advantages of brachytherapy, we propose novel anatomic criteria for the implantation. Increasing evidence supports a paradigm shift in staging and treatment of NVSCC.

Sections du résumé

BACKGROUND UNASSIGNED
Nasal vestibule squamous cell carcinoma (NVSCC) is an ill-defined underestimated condition.
AIM/OBJECTIVE UNASSIGNED
To define the current standard of care.
MATERIAL AND METHODS UNASSIGNED
We review recent acquisitions concerning clinical features and therapeutic approaches.
RESULTS UNASSIGNED
The current AJCC staging system, which attributes to nasal vestibule the same topographic code as nasal cavity proper and the same T-classification criteria as ethmoid, appears inadequate.As for treatment of primary lesions without bone invasion, current evidence suggests that brachytherapy is at least equivalent to surgery and superior to external beams in terms of oncological outcomes, and superior to both modalities in terms of cosmesis and function.
CONCLUSIONS UNASSIGNED
As for classification and staging, the nasal vestibule should be defined as a subsite of the nose and paranasal sinuses, distinct from the 'nasal cavity proper and ethmoid', with specific topographic code and T-classification criteria. This will improve the assessment of prognosis and prevalence, underestimated also because of misdiagnosis with skin cancers.Secondly, brachytherapy should become the new standard for the treatment of primary lesions without bone invasion. To optimize the advantages of brachytherapy, we propose novel anatomic criteria for the implantation.
SIGNIFICANCE UNASSIGNED
Increasing evidence supports a paradigm shift in staging and treatment of NVSCC.

Identifiants

pubmed: 36855802
doi: 10.1080/00016489.2023.2179662
doi:

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

215-222

Auteurs

Francesco Bussu (F)

Otolaryngology Division, Azienda Ospedaliero Universitaria, Sassari, Italy.
Otolaryngology, Department of Medicine, Surgery and Pharmacy, Università di Sassari, Italy.

Luca Tagliaferri (L)

Fondazione Policlinico Universitario ''A. Gemelli'' IRCCS, UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Roma, Italia.

Claudia Crescio (C)

Otolaryngology Division, Azienda Ospedaliero Universitaria, Sassari, Italy.

Davide Rizzo (D)

Otolaryngology Division, Azienda Ospedaliero Universitaria, Sassari, Italy.
Otolaryngology, Department of Medicine, Surgery and Pharmacy, Università di Sassari, Italy.

Roberto Gallus (R)

Mater Olbia Hospital, Olbia, Italy.

Claudio Parrilla (C)

Fondazione Policlinico Universitario "A. Gemelli" IRCCS, UOC Otorinolaringoiatria, Roma, Italia.

Bruno Fionda (B)

Fondazione Policlinico Universitario ''A. Gemelli'' IRCCS, UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Roma, Italia.

Valentina Lancellotta (V)

Fondazione Policlinico Universitario ''A. Gemelli'' IRCCS, UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Roma, Italia.

Gian Carlo Mattiucci (GC)

Mater Olbia Hospital, Olbia, Italy.

Jacopo Galli (J)

Dipartimento Testa-collo e organi di senso, Università Cattolica del Sacro Cuore, Roma, Italia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH